While PD-1/PD-L1 blockade has demonstrated remarkable clinical successes, recent studies suggest that its novel target has a highly attractive therapeutic potential in various immuno-oncological states both as a monotherapy and combinatorial therapy. Shares of Shilpa Medicare Ltd ended at ₹631, up by ₹2.25, or 0.36%, on the BSE.
